Sign inJoin waitlistJoin the waitlist

Dan Zandberg

Associate Division Chief for Clinical Affairs · UPMC Medical Education

Credentials: · · · ·

History

UPMC Medical Education
Present
Head and Neck Cancer Disease Section · UPMC Medical Education
Present
UPMC Medical Education
Present

Medical Oncology
2008–2010
Internal Medicine
George Washington University School of Medicine
2005–2008
Doctor of Medicine
2001–2005

Research

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
Journal for ImmunoTherapy of Cancer · 2019 · 571 citations
Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment
Review · Nature reviews. Cancer · 2023 · 278 citations
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial
JAMA Oncology · 2019 · 255 citations

Robert Ferris
29 papers
Heath Skinner
18 papers
JJ
Jonas Johnson
16 papers
KC
Kevin Contrera
13 papers · 1 as a fellow
SS
Shaum Sridharan
13 papers
Jose Zevallos
10 papers
SK
Seungwon Kim
10 papers
MK
Mark Kubik
9 papers · 3 as a fellow
MS
Matthew Spector
9 papers
David Clump
8 papers
Raja Seethala
8 papers
Umamaheswar Duvvuri
8 papers

Grants

Small Extracellular Vesicles as Biomarkers of Prognosis and Response to Therapy in Head and Neck Cancer
National Institute of Dental and Craniofacial Research · R01
PI · $2.9M · University of Pittsburgh at Pittsburgh
2023–2027
Head and Neck Cancer SPORE
National Cancer Institute · P50
PI · $2.2M · University of Pittsburgh at Pittsburgh
2004–2027
Immune Exclusion in Cancer Immunotherapy
National Institute of Dental and Craniofacial Research · R01
PI · $1.2M · University of Pittsburgh at Pittsburgh
2022–2027
Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $543.4K · University of Pittsburgh at Pittsburgh
1997–2027

Clinical trials

Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC
Principal investigator · Recruiting · Phase 2
Dan Zandberg
2023–2027
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Principal investigator · Recruiting · Phase 2
National Cancer Institute (NCI)
2021–2029
Hemopurifier Plus Pembrolizumab in Head and Neck Cancer
Principal investigator · Terminated
Aethlon Medical Inc.
2020–2022
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
Principal investigator · Recruiting · Phase 2
Dan Zandberg
2020–2032